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Abstract
Background: This study investigates the clinical use of neuroleptics within a general hospital in
acutely ill medical or surgical patients and its relation with dementia three months after admission
compared with control subjects.
Methods: Cases were defined as every adult patient to whom a neuroleptic medication was
prescribed during their hospitalization in our Hospital from February 1st, to June 30th, 1998. A
control matched by age and sex was randomly selected among patients who had been admitted in
the same period, in the same department, and had not received neuroleptics drugs (205 cases and
200 controls). Demographic, clinical and complementary data were compared between cases and
controls. Crude odds ratios estimating the risk of dementia in non previously demented subjects
compared with the risk in non-demented control subjects were calculated.
Results: 205 of 2665 patients (7.7%) received a neuroleptic drug. The mean age was 80.0 ± 13.6
years and 52% were females. They were older and stayed longer than the rest of the population.
Only 11% received a psychological evaluation before the prescription. Fifty two percent were
agitated while 40% had no reason justifying the use of neuroleptic drug. Three months after
neuroleptic use 27% of the surviving cases and 2.6% of the surviving controls who were judged non-
demented at admission were identified as demented.
Conclusions: The most common reason for neuroleptic treatment was to manage agitation
symptomatically in hospitalised patients. Organic mental syndromes were rarely investigated, and
mental status exams were generally absent. Most of neuroleptic recipients had either recognised
or unrecognised dementia.
Background
Neuroleptic drugs are commonly prescribed in acutely ill-
hospitalised patients [1–3]. However, the use of such
medication has not been extensively studied. Agitation
and delirium are major clinical problems in hospitalised
patients, especially in those who are elderly and demented
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and it is significantly more frequent in patients with psy-
chiatric comorbidity or dementia [7,8]. Delirium is also
an predictor of adverse outcomes in older hospital pa-
tients, including longer mean length of hospital stay, poor
functional status and need for institutional care, and mor-
tality.[9]
Non-pharmacological and pharmacological interventions
are effective in controlling the symptoms of delirium in
acutely ill patients [10–15]. Treatments for agitation are
imperfect, and clinicians should be prepared to work
through several in order to find the most suitable for a giv-
en patient and clinical situation.[16] Ideally the use of
pharmacological interventions should be reserved for sit-
uations where other measures have been unsuccessful,
[12,16] however between 9.4 and 42.8% of non-psychiat-
ric patients were prescribed psychoactive medications
during hospitalisation, most of them because of agitation
or delirium [1,3]. Efficacy, side effects, adverse experiences
and strategies of drug selection based on the patient's di-
agnosis have not been frequently studied.
This study investigates the clinical use of neuroleptics
within the medical and surgical departments of a General
tertiary Hospital, to understand how these drugs are used
in this setting and to determine whether the use of these
drugs is an predictor of adverse outcomes or mortality
during hospitalisation, at discharge or three months later.
We collected in a retrospective study clinical features, out-
comes and risk factors from two cohorts of hospitalised
elderly patients who have been treated with and without
neuroleptic drugs during admission.
Materials and Methods
This retrospective case-control study compares patients
admitted to general medical or surgical units who received
neuroleptics with age-sex matched controls who did not.
Case is defined as every patient 18 years of age or older to
whom a neuroleptic medication was prescribed during
their hospitalisation in our Hospital from February 1st, to
June 30th, 1998. Prescriptions for haloperidol (Haloperi-
dol®), chlorpromazine (Largactil®), tiapride (Tiaprizal®),
and thioridazine (Meleril®) were examined.
A control group matched by age (± 10 y) and sex was ran-
domly selected among patients who had been admitted in
the same period and had not received neuroleptic drugs.
These patients were selected between patients admitted
within two weeks of the index case was recruited and in
the same department.
Five cases had no suitable controls.
The following information was obtained via chart review
in cases and controls:
- Demographic characteristics (age, sex),
- Length of hospitalization
- Previous diseases: chronic obstructive lung disease (previ-
ously diagnosed based on clinical criteria), hypertension
(previously diagnosed and treated or systolic pressure
>160 mmHg and/or diastolic pressure >90 mmHg persist-
ently observed during admission after the acute phase), di-
abetes (previously diagnosed and treated or fasting glucose
7 mmol/L (126 mg/dL) in two blood samples after the
acute phase), heart disease (myocardial infarct, congestive
heart failure or valvular disease previously diagnosed by a
physician), atrial fibrillation, dementia or cognitive impair-
ment (previously diagnosed by a physician) and the use of
bladder catheter
- Laboratory studies during admission: plasma levels of
creatinine, potassium, sodium, oxygen, CO2 and bicarbo-
nate.
- Clinical data during admission: fever (temperature over
38°C), surgical procedures, use of bladder catheter, neu-
ropsychological assessment, death and its cause.
- Diagnostic criteria for dementia: A physician (RB) who
searches for specific diagnostic criteria for dementia deter-
mine the presence or absence of dementia based on infor-
mation from neurologic and functional examinations at
admission and 3 months after discharge. Diagnosis of de-
mentia was based on the clinical judgement of the exam-
ining physician, but no standard criteria were applied for
the diagnosis.
- Follow up: Three months after discharge medical records
were reviewed by a physician (RB) who searches for spe-
cific diagnostic criteria for dementia. To be accepted as de-
mented there had to be documented evidence of decline
of intellectual and/or cognitive and social function that
was irreversible with medical or psychiatric treatment.
Death was also recorded. Whenever possible, the cause of
death was ascertained from the hospital records.
Statistical analysis
Demographic, clinical and complementary data were
compared between cases and controls. The two-tailed Stu-
dent's t test for quantitative variables and the χ2 test for di-
chotomous variables were used. The Odds-Ratios and
95% confidence intervals were estimated from the logistic
regression coefficients.Page 2 of 6
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ter admission, we defined an incidence cohort composed
by non demented cases and controls at baseline who were
followed over three months. Newly demented subjects
were enumerated in the neuroleptic and control cohorts.
Crude odds ratios (OR) estimating the risk of dementia in
the neuroleptic group compared with the risk in control
subjects were calculated.
In order to identify predictors of dementia three months
after admission, we performed a logistic regression analy-
ses in which dementia was considered the dependent var-
iable, for both cases and control subjects combined (total
175). Clinically relevant variables and those with statisti-
cal significance (p < 0.1) in the univariate analyses were
introduced as independent variables. A logistic regression
analysis, with backward stepwise procedure and p > 0.10
as the criterion for exclusion, was used to find the best pre-
dictive model of dementia after neuroleptic use during ad-
mission.
All these analyses were performed with SPSS for Windows
version 9.0 (SPSS Inc)
Results
During the study period 2665 patients over 18 years were
admitted at the medical and surgical departments of our
Hospital, and in 205 (7.7%) a neuroleptic drug was pre-
scribed during the stay. One hundred and eighty (88%) of
the study patients received haloperidol as the only neu-
roleptic drug. Twenty-five (12%) had either an alternative
drug or a combination of drugs. Indication for prescribing
neuroleptic drugs were as follows: agitation 107 (52.2%),
impossibility to sleep 8 (3.9%), other 8 (3.8%), none 82
(40%). Sixty-one cases (29.8%) were discharged from the
hospital on a neuroleptic drug. In the cohort, only 22 cas-
es (11%) underwent neuropsychological assessment.
These cases did not differ in age or sex from those who
were not examined, but 20 of them were in a medical serv-
ice and only two in a surgical department (14% versus
4%; OR 3.7 CI95% 0.9–16.7; p = 0.07). Cases to whom
mental status examinations were performed were more
likely to be receiving the drug at discharge (20% versus
9%; OR 2.5 CI95% 1.1–6.3; p = 0.036).
The mean age was 80.0 ± 13.6 years (range 42–102 y)
from cases and 78.3 ± 7.1 (range 51–96 y) from controls;
107 cases and 98 controls were female (52% versus 49 %;
p = 0.551).
Fifty six cases (27.3%) and 16 controls (8%) were de-
mented (OR 1.3 IC 95% 1.1–1.4; p < 0.0001) and 51 cases
(24.8%) and 24 controls (12%) were classified as having
cognitive impairment before hospitalisation. Twenty-two
cases (11%) and 4 controls (2%) did not complete a clin-
ical neurological examination and were not tested.
Mean hospitalisation time was11.2 ± 11.5 days which was
longer than the hospital's average length of stay (5.2 ± 13,
p < 0.0001) and longer than the control group (6.8 ± 6.4,
p < 0.0001).
Cases did not differ significantly from controls in terms of
atrial fibrillation, diabetes mellitus, chronic heart or lung
disease prevalence (Table 1). Hypertension was signifi-
cantly more frequent in controls than in cases (53% ver-
sus 40%; OR 1.7 IC95% 1.3–2.5; p = 0.013). During
admission fever (41% versus 27.6%; OR 1.3 IC 95% 1.1–
1.6; p = 0.007) and the use of bladder catheter (68.6 ver-
sus 30.6; OR 2.2 IC 95% 1.6–3.0; P < 0.0001) were more
frequent in cases than in controls, while surgical proce-
dures (25.3% versus 25.5%; OR 0.7–1.2) did not differ in
both groups (TABLE 1). There were no significantly differ-
ences between groups in the haematological and bio-
chemical complementary studies (data not shown).
Thirty cases and 14 controls died during the admittance
(16% versus 7%; OR 1.4 IC 95% 1.2–1.8; p = 0.007), and
42 cases and 18 controls died during the 3 months follow-
ing discharge (30% versus 12%; OR 3.1 IC 95% 1.7–5.7;
P < 0.0001)
Incident dementia
In order to identify the incidence of dementia three
months after neuroleptic use we compared the surviving
Table 1: Comparison between cases and controls: demographic 
data, previous diseases and clinical data during admission
Cases      
(n = 205)




Mean age, y (SD) 80.0 ± 13.6 78.6 ± 7.1 1.01 (0.9–1.1)
% < 60 y 2 (1%) 2 (1%) 1.03 (0.1–10.2)
%>90 y 16 (4.3%) 9 (4.5%) 1.8 (0.7–4.5)
Females (%) 52% 49% 1.13 (0.6–2.1)
High blood pressure 71 (40%) 109 (53%) 0.7 (0.6–0.9)
Diabetes 35 (19.7%) 51 (24.6%) 0.8 (0.6–1.1)
Heart disease 78 (44%) 96 (46.6%) 0.9 (0.7–1.1)
Atrial fibrillation 42 (23.6%) 46 (22.5%) 1 (0.8–1.3)
Lung disease 63 (35%) 80 (38.8%) 0.9 (0.7–1.1)
Incontinent 80 (46%) 27 (13%) 2.2 (1.7–2.6)
Previous dementia 59 (33%) 15 (7.3%) 2.1 (1.7–2.4)
Fever 76 (41%) 55 (26%) 1.4 (1.1–1.7)
Surgery 49 (25.3%) 52 (24.6%) 1 (0.8–1.3)
Urinary catheter 81 (68.6%) 39 (30%) 2.3 (1.7–3.1)
Death during admission 30 (16%) 15 (7.1%) 1.4 (1.1–1.8)
* chi-square testPage 3 of 6
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the study population 127 cases and 180 controls were
non-demented at admission and of these, 59 subjects
were compared with 116 controls. The difference in the
study population was accounted by 30 who died before 3
months (22 during admission) and 38 with incomplete
information about their neurological status. In the control
group the difference was accounted by 10 who died before
3 months (7 during admission), and 47 who were not
testable (TABLE 2). The 38 lost cases and the 47 lost con-
trols were older than the testable patients (cases: 75.7 ± 17
versus 82.6 ± 11; p = 0.021; controls 79.7 ± 6.5 versus 76.5
± 6.5; p = 0.004) but did no differ in gender or previous
diseases (data not shown).
Sixteen (27%) of the surviving cases and 4 (2.6%) of the
surviving controls who were judged non-demented at ad-
mission were demented three months after admission.
The unadjusted odds of having dementia after admission
in the neuroleptic prescribed group compared with the
odds in the control sample was OR 10.4 95% IC 3.3–32.9;
p < 0.0001. We used a multiple logistic regression model
to estimate de Odds Ratio of dementia adjusting for age,
sex and cardiovascular risk factors (hypertension, diabe-
tes, heart disease). The adjusted Odds ratio was 12.0 95%
IC 3.6–39.
Risk of dementia estimated by logistic model
We use a logistic model to determine predictors of demen-
tia three months after admission. Dementia was consid-
ered as the dependent variable for both non previous
demented case and control subjects combined. Atrial fi-
brillation, diabetes mellitus, hypertension, heart disease,
previous incontinence and use of neuroleptics were used
as independent variables. The overall adjusted OR was
12.5 (IC 95% 3.4–45.2) in neuroleptic group. A subject
(case or control) with previous incontinence has a risk of
dementia 10.6 times (IC 95% 2.0–57.1) the risk of a sub-
ject without incontinence. There are not significantly dif-
ferences between patients with or without diabetes,
hypertension, heart disease or atrial fibrillation.
Discussion
Neuroleptic drugs are commonly prescribed to treat agita-
tion or delirious states in acutely ill hospitalised patients
[1,3]. In our cohort, patients who received neuroleptic
drugs were often elderly, seriously ill, stayed in the hospi-
tal longer and had a higher mortality rate during hospital-
isation and three months later than patients who did not.
There have been few controlled trials about the most com-
monly used drugs to guide therapy in delirium and agitat-
ed patients [1–3,11,14,16–18]. To successfully treat these
conditions, an adequate description of behavioural target
symptoms to be corrected and a thorough investigation to
identify precipitating causes are essential. [8,16,19]. Be-
havioural problems in hospitalised patients may result
from physical illnesses, adverse drug effects, environmen-
tal changes, psychiatric syndromes or dementing illnesses
[5,8,12,13,20–23]. However only 11% of our cases had a
neuropsychological evaluation prior to neuroleptic pre-
scription. Some authors have suggested that physicians
may be reluctant to seek psychiatric consultation in older
patients [24] however a neuropsychological evaluation
could give essential information to ascertain the aetiology
of agitation.
This study shows that neuroleptic drugs were prescribed
to 7% of a general hospital inpatients, although diagnos-
tic indications were discovered only in a few of them. The
lack of documentation supporting a diagnosis justifying
the use of a neuroleptic drug noted in this study has been
observed elsewhere [1,3]. The descriptions of agitation
may seem to be an adequate reason for treatment, howev-
er both dementia and delirium are not an easy diagnosis,
and both are often underdiagnosed in the acute care.
[6,15,25–27]. As neuroleptics are not innocuous
drugs,[28] physicians must recognize that these drugs can
promote important side effects, and prior investigators
have demonstrated than physicians often lack sufficient
knowledge about the therapeutic use and pharmacoki-
netis of these medications. [2,29,30] This study suggests
that more education regarding the use of neuroleptic
drugs is indicated.
Compared with patients to whom neuroleptics are not
prescribed during admission, the risk of being diagnosed
as demented three months later is at least ten times higher
even after adjusting by age and sex. Probably these pa-
tients have a mild cognitive impairment that has not been
previously identified. Some studies have shown that most
of the elderly patients admitted in a general hospital who
have presented delirium could be identified as demented
Table 2: Sample attrition at different steps of the study in non-de-
mented patients.
Cases     
n = 205
Controls    
n = 200
Non-demented at admission 127 (62%) 180 (90%)
Death during admission 22 7
Death during the next three months 
after discharge
8 10
Lost follow up 38 47
Analysed* 59 116
* Surviving non-demented cases with completed examination.Page 4 of 6
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that the early identification of patients with mild cogni-
tive decline could be important as it would allow for some
interventions to improve better quality care.[31]
The study has some design-based limitations. The diagno-
sis of dementia was based on clinical information, and we
did not use any of the standard criteria or neuropsycho-
logical tests that can be uniformly applied. It is probable
that dementia was underdiagnosed, since it is known that
the use of neuropsychological test might uncover a larger
number of clinically unobvious cases. If only the most
overt cases were labelled as demented, one interpretation
is that our estimation describes a minimum frequency.
Supporting the validity of our findings, other studies have
documented acceptable agreement between a clinician's
diagnostic impression and findings from formal mental
function tests, [32] with a sensitivity and specificity of di-
agnosis about 79% and 80%, respectively.[33]
This study, performed in a community hospital may not
be generalizable to other settings, however more studies
are recommended in order to confirm this data and to de-
termine if overuse of neuroleptics is a isolated problem of
several hospitals or a extended medical problem.
This study confirms the high rate of neuroleptics use
among hospitalised patients and its association with ad-
verse outcomes such as prolonged hospital stays. The high
death rate in neuroleptic recipients suggests the fragility of
this group, while the diagnosis of dementia three months
after admission is probably related with a high rate of pre-
vious unrecognised dementia. In spite of the use of these
drugs to treat agitation symptoms, they rarely concur with
a formal diagnosis of cognitive decline or the request of a
neuropsychological consultation. Future research should
explore the effectiveness of both diagnostic and manage-
ment approaches to the confused agitated elder and the





(RB) and (JBG) designed the study, (RB) performed de-
mentia diagnosis (HMA) and (IGA) performed the charts
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